Exact Sciences has been granted a patent for a method of analyzing gene expression in renal cell carcinoma patients. The patent involves measuring levels of RNA transcripts from specific genes, including angiogenesis genes, immune response genes, cell cycle genes, and reference genes, to classify and predict the prognosis of cancer. GlobalData’s report on Exact Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Exact Sciences, Personalized medicine biomarkers was a key innovation area identified from patents. Exact Sciences's grant share as of September 2023 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Method of analyzing gene expression in renal cancer patients
A recently granted patent (Publication Number: US11776664B2) describes a method for analyzing the expression of RNA transcripts of genes in a human renal cancer patient. The method involves measuring the levels of RNA transcripts in a renal tumor sample from the patient. The sample is analyzed for a panel of genes consisting of angiogenesis genes, immune response genes, cell cycle genes, transport genes, cell adhesion/extracellular matrix genes, and reference genes.
The patent claims specify that the method can be used specifically for renal cell carcinoma (RCC), with a particular focus on clear cell renal cell carcinoma (ccRCC). The level of RNA transcripts is measured using quantitative RT-PCR, a technique commonly used in molecular biology to quantify gene expression. The renal tumor sample can be obtained from a biopsy and may be paraffin-embedded and fixed.
The panel of genes analyzed in the method includes various sets of genes related to angiogenesis, immune response, cell cycle, transport, and cell adhesion/extracellular matrix. The patent also mentions the inclusion of reference genes for normalization purposes. The reference genes listed in the claims include AAMP, ARF1, ATP5E, EEF1A1, GPX1, RPS23, SDHA, UBB, RPLP1, GAPDH, and beta-actin.
Overall, this patent describes a method for analyzing gene expression in renal cancer patients, specifically focusing on RCC. By measuring the levels of RNA transcripts in a renal tumor sample and analyzing a panel of genes, this method could potentially provide valuable insights into the molecular characteristics of renal cancer and aid in diagnosis, prognosis, and treatment decisions. The use of quantitative RT-PCR and the inclusion of reference genes ensure accurate and reliable measurements.
To know more about GlobalData’s detailed insights on Exact Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
